DexCom, Inc.
Key Metrics
- Previous Close
- $82.52
- 52-Week Range
- $56.72 – $92.59
- Market Cap
- $29.91B
- P/E (TTM)
- 31.57
- EPS (TTM)
- 2.54
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 11.80
- PEG Ratio
- 1.30
- Return on Equity
- 37.67%
- Return on Assets
- 11.13%
- Gross Margin
- 63.42%
- Operating Margin
- 23.97%
- Profit Margin
- 19.42%
- Current Ratio
- 1.74
- Debt/Equity
- 0.55
- Total Debt
- $1.39B
- Free Cash Flow
- $811.90M
- Revenue Growth
- 11.20%
- Earnings Growth
- 2.60%
- Enterprise Value
- $30.35B
Market Snapshot
About
DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. The company's flagship products, including the Dexcom G6 and G7 systems, provide real-time glucose readings without the need for fingerstick calibration. DexCom's CGM technology uses a small sensor inserted under the skin that transmits glucose data wirelessly to a receiver or smartphone app. The company's systems help patients manage their diabetes more effectively and reduce the risk of dangerous blood sugar fluctuations. DexCom serves both Type 1 and Type 2 diabetes patients and has partnerships with insulin pump manufacturers for integrated diabetes management systems.